青海春天药用资源科技股份有限公司：关于2025年年度报告延期披露的重要公告
公告摘要
- 股票代码：600381
- 股票简称：*ST春天
- 公告编号：2026-032
- 公告时间：2026年4月16日
- 事项：2025年年度报告披露时间延期
公告详情
青海春天药用资源科技股份有限公司（以下简称“公司”）原定于2026年4月21日对外披露《2025年年度报告》。然而，因年度报告的编辑和复核工作量较大，公司目前尚未完成相关工作。秉持认真、审慎的原则，确保信息披露的准确性和完整性，公司决定将2025年年度报告的披露时间延期至2026年4月30日。
对投资者的重要提示
- 报告披露时间延期，可能引发市场对公司经营状况和财务状况的担忧，具有一定的股价波动风险。
- 公司表示对此造成的不便深表歉意，并希望投资者予以理解。
- 公司提示投资者，所有信息以上海证券交易所网站（www.sse.com.cn）以及法定信息披露媒体为准，提醒广大投资者注意投资风险。
潜在的价格敏感因素分析
- 年度报告延期通常会引发市场对公司运营和财务状况的质疑，特别是对于已被ST（特别处理）标识的公司，投资者需高度关注潜在风险。
- 延期披露可能会影响市场信心，导致短期内公司股价波动甚至下跌，建议投资者密切关注后续公告。
结论
公司年度报告的延期披露构成了对投资者的重要信息，可能对二级市场股价产生影响。建议投资者持续关注公司公告并谨慎决策。
免责声明：本文内容仅供信息参考，不构成任何投资建议。投资者应根据自身情况审慎决策，必要时请咨询专业投资顾问。公司所有正式公告以上海证券交易所官方网站及法定信息披露媒体为准。
English Version
Qinghai Spring Medicinal Resources Technology Co., Ltd.: Important Announcement on Delay in Disclosure of 2025 Annual Report
Key Highlights
- Stock Code: 600381
- Stock Abbreviation: *ST Springtime
- Announcement Number: 2026-032
- Date of Announcement: April 16, 2026
- Subject: Delay in Disclosure of 2025 Annual Report
Details of the Announcement
Qinghai Spring Medicinal Resources Technology Co., Ltd. (the “Company”) originally planned to disclose its 2025 Annual Report on April 21, 2026. However, due to the extensive workload involved in compiling and reviewing the report, the company has not been able to complete the relevant tasks as scheduled. In line with its commitment to accuracy and prudence in information disclosure, the company has decided to postpone the disclosure of the 2025 Annual Report to April 30, 2026.
Important Information for Shareholders
- The delay in the annual report’s disclosure may trigger market concerns regarding the company’s operations and financial health, posing a risk of share price volatility.
- The company apologizes for any inconvenience caused and asks for investors’ understanding.
- Investors are advised to rely on information published on the Shanghai Stock Exchange website (www.sse.com.cn) and official disclosure media, and to pay attention to investment risks.
Potential Price-Sensitive Factors
- Delays in annual report disclosure generally raise market doubts about the company’s business and financial position, especially for companies under “Special Treatment” (*ST). Investors should closely monitor potential risks.
- This delay may undermine market confidence and could result in volatility or a drop in the company’s share price in the short term. Investors should follow upcoming announcements closely.
Conclusion
The delay in the company’s annual report disclosure is a matter of significant concern for investors and may impact the company’s share price. Investors are advised to stay informed through official channels and make prudent investment decisions.
Disclaimer: The information above is provided for reference only and does not constitute investment advice. Investors should make decisions based on their own circumstances and consult professional advisors if necessary. All official company disclosures are published on the Shanghai Stock Exchange website and other statutory information disclosure media.
